# OH2 Injection in Combination With HX008 for Melanoma.

> **NCT04616443** · PHASE1,PHASE2 · RECRUITING · sponsor: **Binhui Biopharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** OH2 injection
- **BIOLOGICAL:** HX008 injection

## Key facts

- **NCT ID:** NCT04616443
- **Lead sponsor:** Binhui Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-12-01
- **Primary completion:** 2025-11-30
- **Final completion:** 2025-11-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04616443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04616443, "OH2 Injection in Combination With HX008 for Melanoma.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04616443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*